- Home
- ZEPP vs NTHI Comparison
ZEPP vs NTHI Comparison
Compare ZEPP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZEPP | NTHI |
|---|---|---|
| Founded | 2013 | 2008 |
| Country | Netherlands | United States |
| Employees | N/A | 5 |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 119.7M | 114.6M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZEPP | NTHI |
|---|---|---|
| Price | $5.47 | $4.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 174.8K | 97.5K |
| Earning Date | 05-18-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $778.34 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.85 | $3.71 |
| 52 Week High | $61.50 | $12.99 |
Technical Indicators
Market Signals| Indicator | ZEPP | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 42.48 | 41.80 |
| Support Level | $4.02 | $4.02 |
| Resistance Level | $5.67 | $5.78 |
| Average True Range (ATR) | 0.53 | 0.42 |
| MACD | 0.36 | -0.01 |
| Stochastic Oscillator | 88.59 | 13.63 |
Price Performance
Historical ComparisonAbout ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands. Geographically, the group generates revenue from Asia-Pacific, Europe, North America and others.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.